MA22097A1 - Procede de preparation de polypeptide et procede de fabrication d'un vaccin contre le paludisme . - Google Patents

Procede de preparation de polypeptide et procede de fabrication d'un vaccin contre le paludisme .

Info

Publication number
MA22097A1
MA22097A1 MA22284A MA22284A MA22097A1 MA 22097 A1 MA22097 A1 MA 22097A1 MA 22284 A MA22284 A MA 22284A MA 22284 A MA22284 A MA 22284A MA 22097 A1 MA22097 A1 MA 22097A1
Authority
MA
Morocco
Prior art keywords
polypeptide
manufacture
preparation
malaria vaccine
malaria
Prior art date
Application number
MA22284A
Other languages
English (en)
Inventor
S Gross M
M Gordon D
Richard Hollingda Michael
Original Assignee
Smithkline Beecham Corp
Usa
Biomedical Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Usa, Biomedical Res Inst filed Critical Smithkline Beecham Corp
Publication of MA22097A1 publication Critical patent/MA22097A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA22284A 1989-12-08 1990-12-05 Procede de preparation de polypeptide et procede de fabrication d'un vaccin contre le paludisme . MA22097A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44774689A 1989-12-08 1989-12-08

Publications (1)

Publication Number Publication Date
MA22097A1 true MA22097A1 (fr) 1991-12-31

Family

ID=23777585

Family Applications (1)

Application Number Title Priority Date Filing Date
MA22284A MA22097A1 (fr) 1989-12-08 1990-12-05 Procede de preparation de polypeptide et procede de fabrication d'un vaccin contre le paludisme .

Country Status (18)

Country Link
EP (1) EP0432965A1 (fr)
JP (1) JPH0673097A (fr)
KR (1) KR910011897A (fr)
CN (1) CN1053814A (fr)
AU (1) AU634837B2 (fr)
CA (1) CA2031468A1 (fr)
FI (1) FI906051A7 (fr)
HU (1) HUT56882A (fr)
IE (1) IE904412A1 (fr)
IL (1) IL96579A0 (fr)
MA (1) MA22097A1 (fr)
MY (1) MY105313A (fr)
NO (1) NO905301L (fr)
NZ (1) NZ236357A (fr)
PL (1) PL288140A1 (fr)
PT (1) PT96132A (fr)
ZA (1) ZA909838B (fr)
ZW (1) ZW19090A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ233255A (en) * 1989-04-11 1993-02-25 Chiron Corp Plasmodium cs protein analogues lacking one or more of the repeat epitopes, and containing at least one nonrepeat flanking epitope
US5972351A (en) * 1992-04-03 1999-10-26 Isis Innovation Limited Plasmodium falciparum MHC class I-restricted CTL epitopes derived from pre-erythrocytic stage antigens
CA2141427C (fr) * 1992-07-31 2008-07-22 Mohammed Anjam Khan Expression de proteines hybrides recombinantes dans des bacteries attenueees
GB9401787D0 (en) 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccine compositions
JPH09500540A (ja) * 1993-07-30 1997-01-21 メデヴァ ホールディングス ビー.ヴイ. ワクチン組成物
EP0730466A4 (fr) * 1993-09-10 1999-04-14 Univ New York Compositions et procedes destines a inhiber l'invasion des hepatocytes par les sporozo tes du paludisme
GB9401795D0 (en) * 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccines
GB2295394B (en) * 1994-01-31 1997-09-24 Medeva Holdings Bv DNA encoding a fusion protein comprising the C fragment of tetanus toxin
ATE524735T1 (de) * 2002-11-20 2011-09-15 Sanaria Inc Impfstoff zur vorbeugung gegen malaria

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN86100979A (zh) * 1985-02-07 1986-12-17 史密丝克莱恩贝克曼公司 疟疾疫苗的制备方法
IT1196501B (it) * 1986-07-16 1988-11-16 Eniricerche Spa Polipeptide utile per la preparazione di vaccini per la malaria e di kits diagnostici per la determinazione di affezioni malariche
FI884485A7 (fi) * 1987-01-30 1988-09-29 Smithkline Biologicals S A P. falciparumin sporotsoiitin pintaproteiinin muodostuminen hiivassa
NZ233494A (en) * 1989-05-03 1993-08-26 Smithkline Beecham Corp Polypeptides comprising plasmodium surface protein with a reduced number of repeating immunogenic determinants fused to a carrier protein; vectors coding therefor and vaccines

Also Published As

Publication number Publication date
ZA909838B (en) 1992-05-27
PT96132A (pt) 1991-09-30
KR910011897A (ko) 1991-08-07
ZW19090A1 (en) 1991-04-10
MY105313A (en) 1994-09-30
EP0432965A1 (fr) 1991-06-19
CA2031468A1 (fr) 1991-06-09
JPH0673097A (ja) 1994-03-15
NZ236357A (en) 1993-01-27
HUT56882A (en) 1991-10-28
NO905301D0 (no) 1990-12-07
FI906051L (fi) 1991-06-09
CN1053814A (zh) 1991-08-14
FI906051A7 (fi) 1991-06-09
AU6777490A (en) 1991-06-13
NO905301L (no) 1991-06-10
HU908128D0 (en) 1991-06-28
IE904412A1 (en) 1991-06-19
FI906051A0 (fi) 1990-12-07
IL96579A0 (en) 1991-09-16
PL288140A1 (en) 1991-10-21
AU634837B2 (en) 1993-03-04

Similar Documents

Publication Publication Date Title
MA22894A1 (fr) Procede de preparation d'un vaccin.
NO903264D0 (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat i form av mikropartikler.
IT8919484A0 (it) Metodo per la preparazione di polibutadiene a lavorabilita' migliorata.
MA22668A1 (fr) Procede de preparation d'oxamides .
FR2621785B1 (fr) Procede de preparation d'un roux
NO901232D0 (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat
PT87065A (pt) Process for the preparation of a vaccine against pasteurellosis
NO904513L (no) Fremgangsmaate for fremstilling av et naeringsmiddel.
IT1231574B (it) Procedimento per la fabbricazione di un prodotto decorativo composito e prodotto cosi' ottenuto
CS265391A3 (en) Novel thienodiazepines, process for their preparation and pharmaceutical comprising them
NO921521D0 (no) 10(1-hydroksyetyl)-11-okso-1-azatricyklo/7.2.0.0.3.8/undek-2-en-2-karboksylsyreestere og en fremgangsmaate for fremstilling derav
ZW19090A1 (en) Malaria vaccine
FR2630735B1 (fr) Procede de preparations d'halogenophenols
MA21849A1 (fr) Procede de fabrication d'alkyl - ethoxy - carboxylates .
HU902652D0 (en) Process for the preparation of malaria vaccine
FI902590A7 (fi) Menetelmä 2-oksoindoli-1-karboksamidien valmistamiseksi
FR2602681B1 (fr) Procede de preparation d'un vaccin recombinant contre l'hepatite b
HU903003D0 (en) Process for the production of a medicative preparation
FI902157A7 (fi) Menetelmä 1,6-hekseenidiohappojen valmistamiseksi
PL286929A1 (en) Method of producing a pharmaceutical preparation of the o/w type
FR2671695B1 (fr) Procede de preparation d'un pain surprise et pain surprise ainsi realise.
IT8840135A0 (it) Procedimento per la fabbricazione di piastrelle da rivestimento, e piastrelle cosi' ottenute
FR2655653B1 (fr) Procede de preparation d'halogenoacetals a partir d'enamines.
FI904950A7 (fi) Menetelmä 3-alkoksi-4-hydroksibentsaldehydien valmistamiseksi
ITFI910264A1 (it) Procedimento per la produzione di un bollino farmaceutico od equivalente, e bollino cosi' realizzato